InMed Enters Into Standby Equity Purchase Agreement
InMed Pharmaceuticals (NASDAQ: INM) has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, , managed by Yorkville Advisors Global LP, on December 13, 2024. The agreement allows InMed to sell up to $10 million of common shares over a 36-month period.
The shares will be priced at 97% of the Market Price during a specified three-day pricing period. The total shares issuable are to 19.99% of outstanding shares as of the effective date, and the Investor's beneficial ownership cannot exceed 9.99%. InMed maintains the right to set minimum acceptable prices for share issuances.